FidoCure^® Veterinary Team Blog

Sir Oliver, an 8 year old French Bulldog with TCC, is surviving and thriving thanks to his targeted therapeutic treatment4.5 months from FidoCure™ enrollment, Sir Oliver's latest CT scan showed a 38% reduction in his bladder tumor.

After one year of FidoCure®targeted therapy, Missy showed no evidence of pulmonary metastatic disease.

 

It is clear that the utilization of targeted therapy has proven beneficial in improving patient quality of life, extending survival time with minimal disease progression, and having an overall positive impact on patient care.

After six months of FidoCure® enabled therapy, Adley showed no evidence of pulmonary mass recurrence.

 

A 11 yr old Golden with hemophagocytic histiocytic sarcoma, 38 months in remission. FidoCure® identified a rare tumor suppressor mutation and suggested additional therapy that may have helped target tumor cells.

After more than 20 months of FidoCure® enabled treatment, Lulu has remained free from further metaseses. There has been no evidence of disease recurrence or pulmonary metastasis. Lulu has maintained a positive quality of life while in treatment and achieved extended time with her pet owners.

After FidoCure^® enabled treatment, Sam exceeded the 5-7  month median survival time for splenic hemangiosarcoma by living over one year beyond diagnosis.

With combination therapy that included targeted therapy guided by  FidoCure® genomic sequencing, Heidi has survived over a year following her initial diagnosis of mesothelioma and is still going strong.

With a combination approach that included FidoCure® therapy, Scout has lived for 1.5 years after his initial diagnosis of telangiectatic osteosarcoma.

As you are likely aware, global supply chain issues are causing shortages of crucial raw drug ingredients needed to produce targeted therapy medications. These shortages are having a significant impact on the veterinary compounding pharmacy industry, and we know that you, your patients and pet parents are feeling the effects.

We want you to know that the FidoCure® team shares your sense of urgency and we are working hard to ensure that no dog is left without the cancer treatments it needs.

Providing access to life-saving therapies is one of our core values, and we are committed to putting you and your patients first.